{"log_id": 6867255619536491677, "direction": 0, "words_result_num": 128, "words_result": [{"probability": {"variance": 1e-06, "average": 0.998901, "min": 0.997037}, "location": {"width": 71, "top": 79, "height": 20, "left": 123}, "words": "药物过量"}, {"probability": {"variance": 0.000848, "average": 0.986617, "min": 0.878026}, "location": {"width": 378, "top": 76, "height": 24, "left": 641}, "words": "给药7天(第1天及第7天每日1次)。参数如表1所示"}, {"probability": {"variance": 3.3e-05, "average": 0.997989, "min": 0.9702}, "location": {"width": 480, "top": 96, "height": 22, "left": 118}, "words": "尚缺乏本品用药过量的研究和报道,一旦发生过量,应给予"}, {"probability": {"variance": 1e-06, "average": 0.998882, "min": 0.996439}, "location": {"width": 117, "top": 118, "height": 21, "left": 117}, "words": "对症和支持治疗"}, {"probability": {"variance": 0.000125, "average": 0.991791, "min": 0.970577}, "location": {"width": 75, "top": 108, "height": 21, "left": 734}, "words": "表1健康成"}, {"probability": {"variance": 0.005703, "average": 0.973956, "min": 0.74742}, "location": {"width": 153, "top": 109, "height": 20, "left": 880}, "words": "给药时药代动力学参数"}, {"probability": {"variance": 0.001001, "average": 0.969899, "min": 0.909945}, "location": {"width": 76, "top": 158, "height": 21, "left": 120}, "words": "【临床试验】"}, {"probability": {"variance": 1e-05, "average": 0.998473, "min": 0.984513}, "location": {"width": 481, "top": 177, "height": 22, "left": 117}, "words": "在对516例前列腺增生症引起排尿障碍的中国患者进行的随机、双"}, {"probability": {"variance": 0, "average": 0.999988, "min": 0.999988}, "location": {"width": 18, "top": 178, "height": 18, "left": 706}, "words": "药"}, {"probability": {"variance": 0.000261, "average": 0.99379, "min": 0.9274}, "location": {"width": 470, "top": 199, "height": 20, "left": 117}, "words": "盲、安慰剂对照Ⅲ期临床试验中,口服给予本品1次4mg或安慰剂"}, {"probability": {"variance": 0.000562, "average": 0.992921, "min": 0.864808}, "location": {"width": 479, "top": 218, "height": 21, "left": 116}, "words": "每日2次,给药12周,比较用药前后自觉症状I-PSS评分的改善情"}, {"probability": {"variance": 7.1e-05, "average": 0.995341, "min": 0.963315}, "location": {"width": 467, "top": 238, "height": 22, "left": 116}, "words": "况。501例(本品338例,安慰剂163例)受试者进入有效性评价"}, {"probability": {"variance": 0, "average": 0.999393, "min": 0.998797}, "location": {"width": 33, "top": 240, "height": 21, "left": 657}, "words": "分布"}, {"probability": {"variance": 0.001244, "average": 0.988676, "min": 0.806894}, "location": {"width": 463, "top": 259, "height": 21, "left": 118}, "words": "与给药前相比,本品与安慰剂自觉症状评分分别下降7.17、5.77"}, {"probability": {"variance": 7.9e-05, "average": 0.996974, "min": 0.957498}, "location": {"width": 377, "top": 259, "height": 22, "left": 641}, "words": "赛洛多辛对人血浆蛋白的结合率(体外试验)为9"}, {"probability": {"variance": 5e-06, "average": 0.996376, "min": 0.994497}, "location": {"width": 47, "top": 262, "height": 21, "left": 1076}, "words": "(添加"}, {"probability": {"variance": 0.007618, "average": 0.980111, "min": 0.488375}, "location": {"width": 470, "top": 278, "height": 23, "left": 114}, "words": "统计学上有显著意义(P=0.0099)。511例受试者进入安全性评"}, {"probability": {"variance": 0.000275, "average": 0.988484, "min": 0.944758}, "location": {"width": 377, "top": 280, "height": 22, "left": 644}, "words": "00ng/mL时),主要的结合蛋白为a1-酸性糖蛋白"}, {"probability": {"variance": 6e-06, "average": 0.99823, "min": 0.988641}, "location": {"width": 482, "top": 298, "height": 21, "left": 112}, "words": "价(本品343例,安慰剂168例)。试验中发生的不良反应,本品"}, {"probability": {"variance": 0.000639, "average": 0.984702, "min": 0.934729}, "location": {"width": 85, "top": 300, "height": 20, "left": 655}, "words": "代谢、排泄"}, {"probability": {"variance": 0.000504, "average": 0.990265, "min": 0.864788}, "location": {"width": 862, "top": 319, "height": 22, "left": 116}, "words": "主要为射精障碍7.58%,口干4.37%,头晕3.50%,心动过缓2.04%;赛洛多辛主要利用细胞色素P4503A4(CYP"}, {"probability": {"variance": 0.008561, "average": 0.951117, "min": 0.744424}, "location": {"width": 83, "top": 321, "height": 19, "left": 1038}, "words": "UDP-葡萄"}, {"probability": {"variance": 0.000292, "average": 0.992624, "min": 0.909498}, "location": {"width": 474, "top": 339, "height": 20, "left": 116}, "words": "安慰剂主要为头晕4.17%,皮疹2.98%,心动过缓2.98%,口干2.38%"}, {"probability": {"variance": 1e-06, "average": 0.999342, "min": 0.996489}, "location": {"width": 480, "top": 340, "height": 23, "left": 640}, "words": "糖醛酸转移酶、乙醇脱氢酶及乙醛脱氢酶进行代谢,血浆中主要"}, {"probability": {"variance": 3e-06, "average": 0.999234, "min": 0.991555}, "location": {"width": 477, "top": 359, "height": 21, "left": 116}, "words": "不良反应均为轻中度,停药后即可恢复正常。试验结果显示:本"}, {"probability": {"variance": 9e-06, "average": 0.998137, "min": 0.988851}, "location": {"width": 478, "top": 360, "height": 22, "left": 641}, "words": "代谢物为赛洛多辛葡萄糖醛酸复合体及氧化代谢物。6例健康男性"}, {"probability": {"variance": 0.000178, "average": 0.994034, "min": 0.941125}, "location": {"width": 443, "top": 377, "height": 29, "left": 114}, "words": "品1次4mg每日2次,在给药早期1周后即可明显改善自觉症状"}, {"probability": {"variance": 0.014179, "average": 0.966568, "min": 0.361831}, "location": {"width": 477, "top": 379, "height": 22, "left": 641}, "words": "以[1C标记的赛洛多辛8mg单次口服给药时,相对于血浆中总放"}, {"probability": {"variance": 0.002683, "average": 0.989089, "min": 0.719988}, "location": {"width": 480, "top": 399, "height": 22, "left": 113}, "words": "在日本进行的赛洛多辛与安慰剂的优效性及与盐酸坦索罗辛的非"}, {"probability": {"variance": 0.006596, "average": 0.976096, "min": 0.617132}, "location": {"width": 477, "top": 400, "height": 22, "left": 642}, "words": "射性能AUC0-12,血浆中赛洛多辛,赛洛多辛的葡萄糖醛酸复合体"}, {"probability": {"variance": 0.000124, "average": 0.995882, "min": 0.943531}, "location": {"width": 473, "top": 419, "height": 22, "left": 113}, "words": "劣性随机双盲Ⅲ期临床试验中,对前列腺增生症引起排尿障碍的"}, {"probability": {"variance": 0.004942, "average": 0.974266, "min": 0.684188}, "location": {"width": 480, "top": 419, "height": 25, "left": 639}, "words": "及氧化代谢物的AUC0-12分别为24.0%、21.9%及34.9%。其它代"}, {"probability": {"variance": 4.9e-05, "average": 0.995959, "min": 0.967569}, "location": {"width": 464, "top": 440, "height": 21, "left": 113}, "words": "患者1次4mg、每日2次,给药12周,比较了给药前后的自觉症状"}, {"probability": {"variance": 9.7e-05, "average": 0.996089, "min": 0.947581}, "location": {"width": 479, "top": 440, "height": 23, "left": 639}, "words": "谢物比例均在5%以下。另外,截至给药后240小时,给药放射性"}, {"probability": {"variance": 0.000494, "average": 0.991042, "min": 0.866235}, "location": {"width": 820, "top": 461, "height": 21, "left": 122}, "words": "SS评分的改变。试验结果表明,赛洛多辛不仅在给药1周后的早能的33.5%经尿排泄、54.9%经粪便排泄"}, {"probability": {"variance": 3e-06, "average": 0.998961, "min": 0.992907}, "location": {"width": 462, "top": 480, "height": 21, "left": 117}, "words": "阶段即可改善其自觉症状,而且对重症患者也显示了改善效果"}, {"probability": {"variance": 3.5e-05, "average": 0.996881, "min": 0.968961}, "location": {"width": 478, "top": 482, "height": 22, "left": 639}, "words": "12例高龄男性及9例非高龄男性以本品4mg单次口服给药时,给"}, {"probability": {"variance": 1.1e-05, "average": 0.998309, "min": 0.983809}, "location": {"width": 471, "top": 500, "height": 22, "left": 114}, "words": "另外,在对364例前列腺增生症引起排尿障碍的患者进行的1次4mg"}, {"probability": {"variance": 0.00022, "average": 0.995192, "min": 0.915506}, "location": {"width": 460, "top": 500, "height": 24, "left": 638}, "words": "药后48小时的尿中累积排泄率分别为,赛洛多辛2.3%及2.4%"}, {"probability": {"variance": 7e-06, "average": 0.998143, "min": 0.989954}, "location": {"width": 478, "top": 519, "height": 22, "left": 113}, "words": "每日2次,共52周的长期给药试验,结果确认了本品具有可持续改"}, {"probability": {"variance": 3.5e-05, "average": 0.997313, "min": 0.974512}, "location": {"width": 479, "top": 520, "height": 23, "left": 638}, "words": "赛洛多辛葡萄糖醛酸复合体1.6%及1.8%,氧化代谢物为4.5%及"}, {"probability": {"variance": 0.008986, "average": 0.98104, "min": 0.479693}, "location": {"width": 471, "top": 538, "height": 23, "left": 113}, "words": "善症状的效果和长期用药的安全性,并可稳定地改善自觉症状(I"}, {"probability": {"variance": 0, "average": 0.996544, "min": 0.996544}, "location": {"width": 17, "top": 541, "height": 16, "left": 656}, "words": "9"}, {"probability": {"variance": 0.003558, "average": 0.97494, "min": 0.781851}, "location": {"width": 178, "top": 561, "height": 19, "left": 113}, "words": "PSS评分)及最大尿流率"}, {"probability": {"variance": 2.6e-05, "average": 0.997973, "min": 0.975878}, "location": {"width": 353, "top": 560, "height": 24, "left": 652}, "words": "前列腺增生症引起排尿障碍的患者的药代动力学"}, {"probability": {"variance": 3e-06, "average": 0.99865, "min": 0.995459}, "location": {"width": 76, "top": 600, "height": 21, "left": 113}, "words": "【药理毒理"}, {"probability": {"variance": 7.2e-05, "average": 0.996364, "min": 0.956837}, "location": {"width": 483, "top": 578, "height": 37, "left": 637}, "words": "在日本进行的以前列腺增生症引起的排尿障碍患者为对的长期"}, {"probability": {"variance": 5e-06, "average": 0.998879, "min": 0.987322}, "location": {"width": 480, "top": 601, "height": 22, "left": 638}, "words": "给药试验中,探索性群体药代动力学分析(258例)结果显示,稳"}, {"probability": {"variance": 0, "average": 0.999687, "min": 0.999213}, "location": {"width": 65, "top": 621, "height": 18, "left": 112}, "words": "药理作用"}, {"probability": {"variance": 0.001668, "average": 0.988915, "min": 0.764555}, "location": {"width": 478, "top": 618, "height": 27, "left": 637}, "words": "态下给药2小时后及12小时后推测血浆中赛洛多辛浓度(均值±SD)"}, {"probability": {"variance": 0.020388, "average": 0.952819, "min": 0.439713}, "location": {"width": 469, "top": 639, "height": 23, "left": 111}, "words": "本品阻断分布于下尿路组织前列腺、尿道及膀胱三角区的αA"}, {"probability": {"variance": 0.000435, "average": 0.985647, "min": 0.923222}, "location": {"width": 203, "top": 642, "height": 18, "left": 637}, "words": "分别为24.8±8.0ng/mL及"}, {"probability": {"variance": 8.5e-05, "average": 0.996168, "min": 0.961858}, "location": {"width": 215, "top": 642, "height": 20, "left": 898}, "words": "3ng/mL。血浆中赛洛多辛浓"}, {"probability": {"variance": 0.010249, "average": 0.979861, "min": 0.453845}, "location": {"width": 482, "top": 657, "height": 24, "left": 109}, "words": "肾上腺素受体亚型介导的交感神经系统,可以缓解下尿路组织平"}, {"probability": {"variance": 4.1e-05, "average": 0.996187, "min": 0.977338}, "location": {"width": 467, "top": 660, "height": 21, "left": 637}, "words": "度的影响因素研究结果显示,赛洛多辛清除率可受体重、年龄、CRP"}, {"probability": {"variance": 2.3e-05, "average": 0.99726, "min": 0.976335}, "location": {"width": 988, "top": 676, "height": 26, "left": 110}, "words": "滑肌紧张、抑制尿道内压升高,从而改善前列腺增生症引起的排ALT(GPT)及血清肌酐的影响,分布容积则受体重、年龄"}, {"probability": {"variance": 0, "average": 0.999931, "min": 0.999804}, "location": {"width": 81, "top": 701, "height": 18, "left": 112}, "words": "尿障碍症状"}, {"probability": {"variance": 8.3e-05, "average": 0.995158, "min": 0.962074}, "location": {"width": 470, "top": 699, "height": 22, "left": 638}, "words": "CRP及ALT(GPT)的影响。这些影响因素中,推测ALT(GPT)"}, {"probability": {"variance": 0, "average": 0.999019, "min": 0.998073}, "location": {"width": 66, "top": 721, "height": 17, "left": 110}, "words": "毒理作用"}, {"probability": {"variance": 0.003341, "average": 0.985404, "min": 0.672445}, "location": {"width": 472, "top": 720, "height": 22, "left": 644}, "words": "寸赛洛多辛血药浓度的影响较大,ALT(GPT)的升高(23→83"}, {"probability": {"variance": 0, "average": 0.999306, "min": 0.998739}, "location": {"width": 64, "top": 740, "height": 19, "left": 110}, "words": "长期毒性"}, {"probability": {"variance": 0.010739, "average": 0.979188, "min": 0.411789}, "location": {"width": 462, "top": 740, "height": 24, "left": 637}, "words": "U/L)可使赛洛多辛清除率及分布容积分别降低约47%及27%"}, {"probability": {"variance": 0.002057, "average": 0.985258, "min": 0.767349}, "location": {"width": 740, "top": 758, "height": 23, "left": 112}, "words": "大鼠连续26周(6个月)(1~300mg/kg/天)、犬连续5周(125:肾功能低下者的药代动力学"}, {"probability": {"variance": 1e-06, "average": 0.99861, "min": 0.997296}, "location": {"width": 42, "top": 780, "height": 20, "left": 111}, "words": "个月)"}, {"probability": {"variance": 5.1e-05, "average": 0.996282, "min": 0.962714}, "location": {"width": 613, "top": 777, "height": 24, "left": 195}, "words": "8mg/kg/天)重复经口给药,除轻度肝细胞脂肪变性在日本进行的研究中"}, {"probability": {"variance": 2e-06, "average": 0.998791, "min": 0.994726}, "location": {"width": 274, "top": 779, "height": 23, "left": 842}, "words": "例肾功能低下者(肌酐清除率27"}, {"probability": {"variance": 0.000795, "average": 0.992068, "min": 0.863463}, "location": {"width": 369, "top": 798, "height": 23, "left": 111}, "words": "和高剂量时乳腺增生外,未见本品相关的异常反应"}, {"probability": {"variance": 6.1e-05, "average": 0.997238, "min": 0.975138}, "location": {"width": 117, "top": 803, "height": 16, "left": 636}, "words": " ML/min-49m"}, {"probability": {"variance": 0.00094, "average": 0.989626, "min": 0.867905}, "location": {"width": 280, "top": 803, "height": 20, "left": 831}, "words": "及7例肾功能正常者(肌酐清除率12"}, {"probability": {"variance": 2e-06, "average": 0.999058, "min": 0.995625}, "location": {"width": 252, "top": 818, "height": 22, "left": 108}, "words": "致癌作用、致突变作用和生殖毒性"}, {"probability": {"variance": 4.8e-05, "average": 0.996323, "min": 0.9638}, "location": {"width": 386, "top": 821, "height": 22, "left": 729}, "words": "6mL/min)以本品4mg单次口服给药时,肾功能低"}, {"probability": {"variance": 0.000126, "average": 0.994837, "min": 0.938781}, "location": {"width": 471, "top": 838, "height": 24, "left": 108}, "words": "在一项大鼠经口给药2年致癌性研究中,每天给药剂量达150mg/kg"}, {"probability": {"variance": 0.001568, "average": 0.986665, "min": 0.806721}, "location": {"width": 367, "top": 840, "height": 22, "left": 639}, "words": "下者相对于肾功能正常者的赛洛多辛血药总浓度升高"}, {"probability": {"variance": 0.008201, "average": 0.909117, "min": 0.81856}, "location": {"width": 18, "top": 846, "height": 17, "left": 1081}, "words": "1倍"}, {"probability": {"variance": 4.3e-05, "average": 0.997792, "min": 0.963927}, "location": {"width": 479, "top": 859, "height": 21, "left": 110}, "words": "大约为人类最高推荐剂量(MRHE)的8倍,雄性大鼠出现了甲"}, {"probability": {"variance": 0.027752, "average": 0.891031, "min": 0.498469}, "location": {"width": 91, "top": 861, "height": 20, "left": 650}, "words": "UC0m3.2倍"}, {"probability": {"variance": 0.002817, "average": 0.982689, "min": 0.75464}, "location": {"width": 341, "top": 862, "height": 22, "left": 775}, "words": "血药总浓度的升高可能与药物和血清中α1-酸"}, {"probability": {"variance": 2.6e-05, "average": 0.997871, "min": 0.974884}, "location": {"width": 479, "top": 880, "height": 20, "left": 107}, "words": "状腺滤泡细胞瘤发生率的增加。但在临床试验中,赛洛多辛未改"}, {"probability": {"variance": 0.010087, "average": 0.971192, "min": 0.535121}, "location": {"width": 481, "top": 879, "height": 25, "left": 635}, "words": "性糖蛋白的蛋白结合有关,血药总浓度与血清中α1-酸性糖蛋白"}, {"probability": {"variance": 0.000126, "average": 0.996466, "min": 0.942743}, "location": {"width": 408, "top": 898, "height": 21, "left": 108}, "words": "变TSH或T4水平,且根据甲状腺检查也未发现受到影响"}, {"probability": {"variance": 1.7e-05, "average": 0.997131, "min": 0.982863}, "location": {"width": 479, "top": 901, "height": 20, "left": 634}, "words": "浓度间存在较高相关性。另外,与赛洛多辛药效及不良反应发生"}, {"probability": {"variance": 6e-06, "average": 0.998457, "min": 0.990001}, "location": {"width": 482, "top": 917, "height": 23, "left": 106}, "words": "在一项小鼠经口给药2年致癌性研究中,雄性小鼠每天给药剂量达"}, {"probability": {"variance": 9e-06, "average": 0.998373, "min": 0.986255}, "location": {"width": 365, "top": 921, "height": 20, "left": 637}, "words": "可能直接相关的是游离型赛洛多辛,其浓度的升高"}, {"probability": {"variance": 0, "average": 0.999989, "min": 0.999989}, "location": {"width": 19, "top": 924, "height": 19, "left": 1080}, "words": "倍"}, {"probability": {"variance": 5.6e-05, "average": 0.996979, "min": 0.95714}, "location": {"width": 452, "top": 939, "height": 20, "left": 117}, "words": "00mg/kg,大约为MRHE的9倍,在雄性小鼠中未见致癌作用"}, {"probability": {"variance": 0.010892, "average": 0.955344, "min": 0.545029}, "location": {"width": 288, "top": 939, "height": 23, "left": 634}, "words": "AUCa-2.0倍)小于药物总浓度的升高"}, {"probability": {"variance": 1.6e-05, "average": 0.998124, "min": 0.98003}, "location": {"width": 481, "top": 959, "height": 20, "left": 107}, "words": "在细菌回复突变试验、小鼠淋巴瘤细胞遗传基因突变试验、中国"}, {"probability": {"variance": 0.000143, "average": 0.99595, "min": 0.937969}, "location": {"width": 481, "top": 978, "height": 20, "left": 107}, "words": "仓鼠培养细胞的染色体畸变试验、小鼠的微核试验以及肝UDS试"}, {"probability": {"variance": 0.000728, "average": 0.980904, "min": 0.942757}, "location": {"width": 43, "top": 978, "height": 21, "left": 643}, "words": "贮藏】"}, {"probability": {"variance": 5e-06, "average": 0.998098, "min": 0.990555}, "location": {"width": 480, "top": 999, "height": 19, "left": 105}, "words": "验中,仅在中国仓鼠培养细胞的染色体畸变试验的非代谢活化的"}, {"probability": {"variance": 2e-06, "average": 0.998847, "min": 0.994762}, "location": {"width": 169, "top": 1000, "height": 20, "left": 636}, "words": "常温、遮光、密封保存"}, {"probability": {"variance": 0.000727, "average": 0.991989, "min": 0.863996}, "location": {"width": 483, "top": 1019, "height": 20, "left": 105}, "words": "短期处理法中,在显示细胞毒性的500μg/mL以上高浓度时,才"}, {"probability": {"variance": 3e-06, "average": 0.998331, "min": 0.993266}, "location": {"width": 316, "top": 1039, "height": 20, "left": 108}, "words": "出现阳性反应,其他所有的试验均呈现阴性"}, {"probability": {"variance": 7.4e-05, "average": 0.993195, "min": 0.978785}, "location": {"width": 53, "top": 1039, "height": 22, "left": 633}, "words": "【包装】"}, {"probability": {"variance": 5e-05, "average": 0.995476, "min": 0.973566}, "location": {"width": 482, "top": 1059, "height": 21, "left": 106}, "words": "雄性大鼠赛洛多辛给药15天,在每天20mg/kg(约为MRHE的2"}, {"probability": {"variance": 5e-06, "average": 0.998264, "min": 0.992505}, "location": {"width": 307, "top": 1061, "height": 23, "left": 634}, "words": "高密度聚乙烯塑料瓶,14粒/瓶;28粒/瓶"}, {"probability": {"variance": 1.8e-05, "average": 0.997795, "min": 0.979589}, "location": {"width": 482, "top": 1077, "height": 24, "left": 105}, "words": "倍)的高剂量下导致了生殖能力的降低,停药2周后可逆转。每天"}, {"probability": {"variance": 4e-05, "average": 0.99698, "min": 0.972544}, "location": {"width": 450, "top": 1099, "height": 21, "left": 105}, "words": "给药6mg/kg未发现任何影响。该结果的临床相关性尚未明确"}, {"probability": {"variance": 0.001249, "average": 0.977756, "min": 0.916619}, "location": {"width": 56, "top": 1099, "height": 22, "left": 641}, "words": "有效期】"}, {"probability": {"variance": 0, "average": 0.910225, "min": 0.910225}, "location": {"width": 18, "top": 1116, "height": 17, "left": 104}, "words": "在"}, {"probability": {"variance": 0.000326, "average": 0.993197, "min": 0.908341}, "location": {"width": 465, "top": 1120, "height": 20, "left": 108}, "words": "在雌性大鼠的生殖能力研究中,每天20mg/kg(约为MRHE的"}, {"probability": {"variance": 0.00139, "average": 0.970094, "min": 0.907888}, "location": {"width": 47, "top": 1120, "height": 20, "left": 636}, "words": "36个月"}, {"probability": {"variance": 7e-06, "average": 0.998322, "min": 0.987791}, "location": {"width": 479, "top": 1140, "height": 19, "left": 105}, "words": "至4倍)的高剂量导致了发情周期的改变,但是对生殖能力没有影"}, {"probability": {"variance": 3e-06, "average": 0.998296, "min": 0.993507}, "location": {"width": 480, "top": 1159, "height": 20, "left": 104}, "words": "响。每天给药6mg/kg未发现对发情周期的影响。在雄性大鼠生"}, {"probability": {"variance": 1e-06, "average": 0.999164, "min": 0.997945}, "location": {"width": 73, "top": 1159, "height": 20, "left": 639}, "words": "执行标准"}, {"probability": {"variance": 0.000162, "average": 0.995093, "min": 0.940736}, "location": {"width": 483, "top": 1178, "height": 22, "left": 104}, "words": "殖能力研究中,每天600mg/kg(为MRHE的65倍)给药一个月"}, {"probability": {"variance": 0, "average": 0.997981, "min": 0.997981}, "location": {"width": 15, "top": 1183, "height": 15, "left": 644}, "words": "B"}, {"probability": {"variance": 1e-06, "average": 0.999358, "min": 0.997926}, "location": {"width": 253, "top": 1198, "height": 21, "left": 105}, "words": "后精子活力和数量出现了明显降低"}, {"probability": {"variance": 8.7e-05, "average": 0.992974, "min": 0.974411}, "location": {"width": 86, "top": 1219, "height": 20, "left": 631}, "words": "【批准文号】"}, {"probability": {"variance": 4.9e-05, "average": 0.995223, "min": 0.981693}, "location": {"width": 91, "top": 1238, "height": 24, "left": 108}, "words": "药代动力学"}, {"probability": {"variance": 0.001228, "average": 0.967131, "min": 0.898524}, "location": {"width": 94, "top": 1241, "height": 19, "left": 632}, "words": "国药准字H20"}, {"probability": {"variance": 4e-05, "average": 0.997159, "min": 0.981645}, "location": {"width": 116, "top": 1259, "height": 20, "left": 122}, "words": "吸收、血药浓度"}, {"probability": {"variance": 0.001832, "average": 0.98176, "min": 0.816158}, "location": {"width": 471, "top": 1278, "height": 22, "left": 105}, "words": "对中国健康成年男性(每组10例)以本品4-12mg单次口服给药时"}, {"probability": {"variance": 6.6e-05, "average": 0.994604, "min": 0.976923}, "location": {"width": 84, "top": 1280, "height": 19, "left": 632}, "words": "【生产企业】"}, {"probability": {"variance": 1.5e-05, "average": 0.998024, "min": 0.980289}, "location": {"width": 849, "top": 1299, "height": 22, "left": 103}, "words": "赛洛多辛基本具有线性药代动力学特征。本品4mg单次口服给药企业名称:第一三共制药(北京)有限公司"}, {"probability": {"variance": 2e-05, "average": 0.997524, "min": 0.979609}, "location": {"width": 350, "top": 1319, "height": 22, "left": 100}, "words": "时,血浆中血药浓度变化如图1所示。参数见表"}, {"probability": {"variance": 1.6e-05, "average": 0.99722, "min": 0.982717}, "location": {"width": 379, "top": 1319, "height": 23, "left": 631}, "words": "生产地址:北京市北京经济技术开发区永昌中路5号"}, {"probability": {"variance": 0.000153, "average": 0.990276, "min": 0.966207}, "location": {"width": 135, "top": 1340, "height": 20, "left": 631}, "words": "邮政编码:100176"}, {"probability": {"variance": 0.003199, "average": 0.981919, "min": 0.778206}, "location": {"width": 191, "top": 1361, "height": 18, "left": 631}, "words": "电话:(+86)10-678"}, {"probability": {"variance": 0, "average": 0.999381, "min": 0.998652}, "location": {"width": 102, "top": 1380, "height": 20, "left": 630}, "words": "咨询电话:40"}, {"probability": {"variance": 0, "average": 0.998221, "min": 0.998115}, "location": {"width": 17, "top": 1384, "height": 16, "left": 783}, "words": "28"}, {"probability": {"variance": 0.000116, "average": 0.993271, "min": 0.958211}, "location": {"width": 229, "top": 1402, "height": 18, "left": 629}, "words": "传真:(+86)21-60397399"}, {"probability": {"variance": 4e-06, "average": 0.997771, "min": 0.995742}, "location": {"width": 67, "top": 1421, "height": 20, "left": 631}, "words": "网址"}, {"probability": {"variance": 0.000245, "average": 0.989937, "min": 0.962843}, "location": {"width": 80, "top": 1503, "height": 20, "left": 476}, "words": "2530"}, {"probability": {"variance": 2.4e-05, "average": 0.994172, "min": 0.988242}, "location": {"width": 60, "top": 1517, "height": 20, "left": 335}, "words": "时间(h"}, {"probability": {"variance": 0.000216, "average": 0.994081, "min": 0.921883}, "location": {"width": 437, "top": 1545, "height": 21, "left": 126}, "words": "图1健康成年男性单次空腹口服4mg赛洛多辛血浆浓度一时间曲线"}, {"probability": {"variance": 0.00029, "average": 0.994156, "min": 0.911962}, "location": {"width": 486, "top": 1578, "height": 23, "left": 98}, "words": "对10例中国健康成年男性口服赛洛多辛1次4mg、每日2次,连续"}, {"probability": {"variance": 0.004453, "average": 0.95746, "min": 0.841924}, "location": {"width": 42, "top": 1582, "height": 18, "left": 1072}, "words": "K2-2"}], "language": 3}